Ophthotech Corp. (OPHT)

[Klinsmann]

Slow and steady wins the race here, bottom in, should see a nice bounce during the next weeks

[Emptyhead]

We have Liftoff. There is so much money coming into our markets. This will be a nice bounce.

[RISK-TAKER]

Took a position... Goldman upgraded mid December after the fall..
Must of lost a bunch..needed buyers.. See a release coming..

[Emptyhead]

OPHT: Getting ready for an entry. Yum Yum

[naturalborninvestor]

OPHT Pincher forming

[Trend-Setter]

A good sign showing vote of confidence towards the company.

GL

[Derek ops]

Huge rally into the close! nice bounce off those lows

[naturalborninvestor]

Hedge funds buying up the float. Love it.


Stonepine Capital Management reports 6.4% beneficial ownership in OPHT
http://ih.advfn.com/p.php?pid=nmona&article=73511128&symbol=OPHT

[Derek ops]

losing support, not good. dump city this hour. may start to drop harder Id be careful here.

[Derek ops]

uh oh she's slipping now..

[alchemytrader]

SVP wouldnt have sold shares this low if that were the case.

[alchemytrader]

BS.

[here4beer]

Inside info

[alchemytrader]

based on what?

[Power of Emouna]

Sure does! Shouldn't be to long before we head back north! Patience it will happen soon enough! $$$OPHT

[here4beer]

looks ready for a major pop

[Derek ops]

not sure on which way this moves on short term basis so for now just playing this channel from 4.80 to around 5.00

its been good about bottoming lower 4.80s and bouncing. we will see if that continues to hold true. great day trades on this one all week.

[jcbaby]

somebody knows somethings coming this play soon?

[naturalborninvestor]

Billionaire Israel Englander acquired 1.8m shares or 5.2% beneficial ownership as of Dec. 20th.

As of the close of business on December 20, 2016, Millennium Management and Mr. Englander may be deemed to have beneficially owned 1,843,693 shares of the Issuer’s Common Stock or 5.2% of the Issuer’s Common Stock outstanding (see Item 4(a) above), which percentage was calculated based on 35,697,696 shares of Common Stock outstanding as of November 4, 2016, as per the Issuer’s Form 10-Q dated November 8, 201

http://ih.advfn.com/p.php?pid=nmona&article=73351492


Follow the money...

[MARINO]

OPHT so cheap

[Trend-Setter]

Novartis acquires Encore Vision, Inc.

Who's next?

http://inpublic.globenewswire.com/releaseDetails.faces?rId=2066499

[judasgoat98]

lol class action suit get out of here shorty

[IPO$]

When will the investigation turn into class action lawsuit on this one? All of a sudden, the drug fails in phase 3 when it looked good in 1 and 2?

[MARINO]

Stock should be $6 minimum

[Klinsmann]

Some are good for a quick flip, this one is still searching for a bottom. May last some weeks for 6$+ again. But it´s going to happen...

[MARINO]

Crazy oversold.

[Giovanni]

Ophthotech Corp (NASDAQ: OPHT) has determined to implement a reduction in personnel to focus on an updated business plan involving an expected workforce of approximately 20 to 30 employees. The Company has also determined to stop treating patients who are in the second twelve months of both its Phase 3 clinical trials (OPH1002 and OPH1003) evaluating the safety and efficacy of 1.5 mg of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy (the “Fovista Phase 3 Lucentis Trials”) for the treatment of wet age-related macular degeneration (“AMD”), with respect to which the Company announced top-line results on December 12, 2016. The Company’s Phase 3 clinical trial (OPH1004) evaluating the safety and efficacy of 1.5 mg of Fovista® administered in combination with Eylea® or Avastin® compared to Eylea® or Avastin® monotherapy for the treatment of wet AMD is fully enrolled and remains ongoing. In addition, the Company has determined to stop treating patients in its additional clinical trials evaluating the potential additional benefits of Fovista® administered in combination with anti-vascular endothelial growth factor, or VEGF, drugs in wet AMD patients, which the Company has referred to collectively as the “Fovista Expansion Studies”. Management and the Board of Directors of the Company continue to actively review, refine and update the Company’s business plan and consider the related impact on operational, financial and development matters, including with respect to each of the Company’s product development programs.

The Company’s Board of Directors committed to this course of action on December 15, 2016 after considering the impact of the top-line results of the Fovista Phase 3 Lucentis Trials. The reduction in personnel is expected to involve approximately 125 to 135 employees. The Company expects to establish a severance program for employees affected by the reduction in personnel and to substantially complete the reduction in personnel during the first and second quarters of 2017 as part of implementing its updated business plan.

[Giovanni]

They needed to take the tax loss

this year..

[alchemytrader]

they probably took close to a 90% loss on their investment.

that doesnt look too good on the stock if they did that.

10% holders just dont take those types of losses if they think the stock will bounce.

[Fallingknife75]

I like seeing the Form 4 from Friday; A 10% holder sold all of their shares Wednesday and Thursday (3.6m shares). It is a good sign of capitulation and relieves a big chunk of selling pressure.

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11741326

Looking forward to next week,

Knife

[Giovanni]

OPHT fired 130 people on Friday...

Conserving $$$ big time



Ophthotech Corp (NASDAQ: OPHT) has determined to implement a reduction in personnel to focus on an updated business plan involving an expected workforce of approximately 20 to 30 employees. The Company has also determined to stop treating patients who are in the second twelve months of both its Phase 3 clinical trials (OPH1002 and OPH1003) evaluating the safety and efficacy of 1.5 mg of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy (the “Fovista Phase 3 Lucentis Trials”) for the treatment of wet age-related macular degeneration (“AMD”), with respect to which the Company announced top-line results on December 12, 2016. The Company’s Phase 3 clinical trial (OPH1004) evaluating the safety and efficacy of 1.5 mg of Fovista® administered in combination with Eylea® or Avastin® compared to Eylea® or Avastin® monotherapy for the treatment of wet AMD is fully enrolled and remains ongoing. In addition, the Company has determined to stop treating patients in its additional clinical trials evaluating the potential additional benefits of Fovista® administered in combination with anti-vascular endothelial growth factor, or VEGF, drugs in wet AMD patients, which the Company has referred to collectively as the “Fovista Expansion Studies”. Management and the Board of Directors of the Company continue to actively review, refine and update the Company’s business plan and consider the related impact on operational, financial and development matters, including with respect to each of the Company’s product development programs.

The Company’s Board of Directors committed to this course of action on December 15, 2016 after considering the impact of the top-line results of the Fovista Phase 3 Lucentis Trials. The reduction in personnel is expected to involve approximately 125 to 135 employees. The Company expects to establish a severance program for employees affected by the reduction in personnel and to substantially complete the reduction in personnel during the first and second quarters of 2017 as part of implementing its updated business plan.

[Klinsmann]

Got a starter toady, some strength above 4,70

[girlfriend]

I got stopped out for the 3rd time…LOL.

I think I will wait for this to settle.

But I saved $102.45 by switching to Geico.

[budmgd]

no hell no...I bailed this morning..hit my stop loss.

time to move on!

[T695]

Doesn't look like the market see any value at these levels

[Klinsmann]

Same here. Gonna need some more time to settle. Wouldn't buy in so far, another 20-30% dip still possible

[Fallingknife75]

Exactly; From the last 10Q even after paying off "Current Liabilities" I have them at $7.33/sh in cash (and I rounded up the O/S to 36m). Happy to accumulate here and wait for the recovery.

All the best,

Knife

[budmgd]

well..except for the fact that just with cash and equiv on hand the stock is worth around $8 /share....but no worries.

[T695]

New 52week low coming tomorrow IMO.... There's no reason this should bounce, only reasons to go sub dollar

[dkl165]

I am going for the bounce too! Anticipate it to be a reasonable bounce!

[dkl165]

I did too. I think it will bounce back up. Do you really figure it will bounce back in 1 week? I figured 2-3 weeks. Maybe even until Feb.

[Jonas3]

Hopefully.. I'm in at 5.12, so at the borderline bagholder stage

[naturalborninvestor]

right, then they will look awesome

[Jonas3]

... until tomorrow

[naturalborninvestor]

Not if u added 4.90's . Actually looks pretty nice.

[JediPadawan]

Disappointing stock....

[poonch1ne]

Yep!

[Klinsmann]

Nope... Maybe in 3-4 weeks with fitting news

[budmgd]

you are spot on....watched this happen with nvax just a few weeks ago. dropped huge on failed trial..had a nice bounce days after

agree as well about the cash on hand. I think it should be enough to drive a short term bounce once peeps take a look at it.

this $5 level is interesting. was no doubt that if the pps got close, they would drop it below to take out stops. now that has been done, let's see if we get a pop back over.

Either way I have a hard stop on this and won't take much loss! LOL

glty!

[girlfriend]

I added a few more under 5 don't have a large position by any means but….OPHT reminds me of other wasted bios that cratered like CMRX, FOLD, TTPH, ….and I could go on and on and on.

Even though at 5 here the cash on hand etc suggests OPHT is a good value but it may be a value trap instead. What do they have left in terms of trials and near term catalysts before the cash is eaten up?

Well….good luck to all. I just want my bounce!